JD.com's Low Profitability in Focus as Traders Brace for Results
Investors are prepared for a big jolt in battered shares of JD.com Inc. following an earnings report from the Chinese e-commerce company, which is mounting a costly foray into food delivery.
Options traders are pricing in a 6.9% move in the Hong Kong-listed stock in either direction after the results due later Tuesday, versus an average 4.2% move following the last eight quarterly reports. Its shares are down 22% from a March high, underperforming all but two members of the Hang Seng Tech Index.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
China's independent oil companies boost investments in Iraq
Chinese independent oil companies are intensifying their activities in Iraq, aiming to double their production to 500,000 barrels per day (bpd) by 2030, according to a Reuters report. This strategic move comes as some global majors have scaled back from these markets, which are traditionally dominated by China's state-run entities. The smaller Chinese producers, led by industry veterans, are drawn to Iraq by more attractive contract arrangements and the potential to leverage lower costs and faster project development. Geo-Jade Petroleum, United Energy Group, Zhongman Petroleum and Natural Gas Group, and Anton Oilfield Services Group have secured half of Iraq's exploration licences in recent rounds. Currently, China's CNPC is a major player, responsible for more than half of Iraq's production at large oilfields such as Haifaya, Rumaila and West Qurna 1. These companies are recognised for their rapid project execution, which appeals to the Iraqi Government. Their increasing presence signifies a shift for Iraq, which is under pressure to expedite energy projects and has previously resisted increasing Chinese influence over its oilfields. Furthermore, the agility and risk tolerance of these smaller companies allow them to develop oilfields in two to three years, significantly faster than Western counterparts. Iraq's improved political stability and investment climate are cited by executives as key factors in attracting both Chinese and Western companies. The country is seeking to significantly boost its oil output, targeting more than six million barrels per day by 2029. Iraq's shift from fixed-fee agreements to profit-sharing contracts has been instrumental in attracting Chinese independents. Geo-Jade Petroleum CEO Dai Xiaoping was quoted as saying: 'Chinese independents have much lower management costs compared to Western firms and are also more competitive versus Chinese state-run players.' Despite concerns over transparency and technical standards, the cost-effective approach of Chinese companies remains attractive to Iraq. While some Western companies are making a comeback, with TotalEnergies and bp planning significant investments, the trend of Chinese operators' expansion in Iraq's oil sector is clear. In May, a consortium spearheaded by Geo-Jade decided to fund the South Basra endeavour, encompassing the enhancement of the Tuba field in Iraq's southern region to a capacity of 100,000bpd. This included the construction of a refinery capable of processing 200,000bpd. With an investment pledge of $848m (6.09bn yuan), Geo-Jade is set to rejuvenate production at the predominantly idle field, aiming to achieve production of 40,000bpd by mid-2027. "China's independent oil companies boost investments in Iraq" was originally created and published by Offshore Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
US-China tensions offer new opportunity for APAC biotechs, report suggests
Investors are increasingly focused on biotech companies outside of China operating in the Asia-Pacific (APAC) market, according to a report by management consulting firm Bain & Company. Homing in on Singapore specifically, the report states that rising players within the APAC region are drawing in investors through their political neutrality, protection of intellectual property (IP) and strong healthcare infrastructure. This trend is further driven by continued investment by the Singaporean Government, which has handed out $25bn in early-stage funding between 2021 and 2025 through its Research Innovation and Enterprise 2025 (RIE2025) scheme. Singapore is also aiming to bridge the gap between academia and industry through its A*STAR scheme, which is designed to encourage the translation of research into commercially viable drugs. These initiatives are designed to de-risk the early-stage development process, laying the foundations for future venture capital investment. Changing tides in the biotech sector The 2020s have been a tough period for the biotech industry, with many companies failing to obtain funding amid growing geopolitical instability and a sharpened investor focus on late-stage therapies. However, things may be looking up for the sector, with a GlobalData report finding that biotech companies obtained $8.52bn in 2024 through initial public offerings (IPOs) — a marked increase from the $5.06bn raised in 2023. Though the US and China continue to dominate the market, rising tensions between the nations could shift the balance towards politically neutral and stable nations, stated Alison Labya, senior pharma business fundamentals analyst at GlobalData. Labya said: 'Singapore's alignment with international pharmaceutical standards reduces legal and regulatory risk, increasing investor confidence in the commercial potential of innovative drugs." As the US continues to face geopolitical uncertainty, NIH funding cuts and mass regulatory layoffs, Labya noted that APAC players — particularly Singapore — are emerging as attractive alternatives for biotech investors, offering a more stable environment conducive to bringing drugs to market. Biotech's future moving forward Even amidst the growing geopolitical tensions between the US and China, Labya stated that China will likely remain the dominant force in Asian biotech. 'China remains resilient in the face of Trump's trade war, notably retaliating with 125% tariffs on US goods in April 2025,' Labya commented. Through this response, both countries reduced their import tariff rates, highlighting China's capacity to influence trade and policy outcomes. Large pharma has also continued to engage with the Chinese biotech market, with 28% of innovator drugs now being picked up from the nation, according to a report from GlobalData. For APAC countries such as Singapore to compete with China, Labya noted that biotechs in the region must penetrate the US and EU, requiring expertise into the FDA and EMA's regulatory frameworks, as well as the development of international partnerships. "US-China tensions offer new opportunity for APAC biotechs, report suggests" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
5 minutes ago
- Yahoo
Marriott earnings top estimates despite economic uncertainty
- Marriott International (NASDAQ:MAR) narrowed its full-year earnings outlook on Tuesday, as the hotel operator flagged ongoing headwinds from federal government spending cuts and weaker business travel, although second-quarter earnings still topped expectations. Revenue per available room, a key metric that gauges how effectively a hotelier is filling up rooms, was flat in the U.S. and Canada compared to a year ago, as these trends were somewhat offset by "continued strength" in luxury expenditures. Domestic travel in the U.S. has also been weighed down by ongoing murkiness surrounding U.S. tariffs, which have led many consumers to rein in expenditures. But globally, the measure, known as RevPAR, increased by 1.5% during the quarter, thanks to resilient leisure travel demand. Outside of the United States, growth was particularly solid in the Asia-Pacific and Europe, Middle East, and Africa regions, Marriott said. The comment mirrors recent statements from some airlines, who have suggested that improvements in the geopolitical outlook have helped to boost bookings. Despite worries around the impact of President Donald Trump's trade war on travel activity, executives in the airline industry have said demand has started to show signs of stabilizing after slipping earlier this year. In a statement, Marriott CEO Anthony Capuano said the firm's quarterly results were "strong" despite "heigtened macro-economic uncertainty." Adjusted earnings per share for the period came in at $2.65, up from $2.50 a year earlier and above estimates of $2.61. Revenue grew by 4.7% to $6.74 billion, exceeding expectations as well. Shares in Marriott rose by more than 6% in premarket U.S. trading on Tuesday. For the full year, Marriott said it now expects adjusted earnings before interest, taxes, depreciation and amortization to be between $5.31 billion and $5.40 billion. It had previously guided for $5.29 billion to $5.43 billion. Related articles Marriott earnings top estimates despite economic uncertainty Risks Rising? Smart Money Dodged 46%+ Drawdowns on These High-Flying Names 7 Undervalued Stocks on the Rise With 50%+ Upside Potential Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
